H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Cogent Biosciences (COGT) to $21 from $22 and keeps a Buy rating on the shares following the Q2 report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences Reports Increased Losses Amidst Ongoing Development
- Promising Pipeline and Financial Stability Drive Buy Rating for Cogent Biosciences
- Cogent Biosciences reports Q2 net loss $73.529M vs $58.95M last year
- Promising Developments and Undervaluation Drive Buy Rating for Cogent Biosciences
- Cogent Biosciences price target raised to $22 from $15 at Citi